Current Atherosclerosis Reports

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	103
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes	100
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?	98
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	81
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	79
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	63
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	62
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	62
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?	62
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	60
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease	58
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	58
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	53
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	53
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	52
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart	46
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis	45
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm	44
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	44
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event	42
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	41
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	39
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?	38
The Emerging Specialty of Cardio-Rheumatology	36
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease	36

Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?	34
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	34
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	33
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	33
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	32
Percutaneous Coronary Interventions in Women	32
Inflammation in the Peri-ACS Period: Ready for Prime Time?	31
Lipoprotein(a): from Causality to Treatment	30
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	30
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	29
Myeloid Cells in Abdominal Aortic Aneurysm	29
The Role of Sleep in Cardiovascular Disease	28
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	28
Low LDL-C: Is It all Good News?	27
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	26
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	24
Importance of Nutrition Security to CVD Prevention Efforts in the USA	24
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	24
Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?	24
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	23
Childhood Hypertriglyceridemia: Is It Time for a New Approach?	23
Transgender Cardiovascular Health: Practical Management for the Clinician	22
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	22
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	22
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	22
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	20
Update on Plant-Based Diets and Cardiometabolic Risk	20
Transforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges	20
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	20
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	20
Correction to: High-Density Lipoproteins and Serum Amyloid A (SAA)	20
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference	19
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	18
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	18
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	18
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	17
Gene Regulatory Networks in Coronary Artery Disease	17
Factors Affecting Circulating Phytosterol Levels: Toward an Integrated Understanding of Atherogenicity and Atheroprotection by Dietary and Circulating Phytosterols	17
Clinical Management of Dyslipidemia in Infants and Toddlers	17
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor	17
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review	17
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	17
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	17
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?	17
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	16
Cardiovascular Disease in the Middle East and North Africa, 1990–2021: Burden, Trends, and Risk Factors	16
HIV and Cardiovascular Disease Burden in Young Adults (18–25 years): A Review of Current Evidence	16
Expanding Clinical Indications for Cardiac CT: A Review of Its Current Utility in American and European Guidelines	15
What Causes Premature Coronary Artery Disease?	15
Cardiovascular Health and Disease in the Pakistani American Population	15

Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis	15
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference	15
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	15
High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review	15
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	14
Utility of FFRCT in Patients with Chest Pain	14
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	14
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	14
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults	14
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	14
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins	14
Bempedoic Acid: for Whom and When	14
Natural Sirtuin1 Activators and Atherosclerosis: an Overview	14
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	14
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?	13
Serial Coronary CTA for Monitoring Response to Lipid-Lowering Therapy: A Narrative Review	13
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	13
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	13
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	13
Dietary Management of Atherogenic Dyslipidemia	13
Fixed Combination for the Treatment of Dyslipidaemia	13
Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches	12
Circular RNA role in Atherosclerosis Development and Progression	12
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk	12
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	12
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention	12
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned	12
Correlation Between Oral Bacteria and Atherosclerotic Thrombotic Disease: Advances in Animal Model Studies	12
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation	11
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?	11
Apheresis: What Should a Clinician Know?	11
Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults	11
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis	11
Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies	11
Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes	11
Statins and Inflammation	11
The TICE Pathway: Mechanisms and Potential Clinical Applications	10
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions	10
Recent Advances in Coronary Computed Tomography Angiogram: The Ultimate Tool for Coronary Artery Disease	10
Unveiling the Sex-Based Divide: Exploring Sex Differences in Peripheral Artery Disease	10
Imaging Approaches to the Diagnosis of Vascular Diseases	10
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia	10
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges	10
S-Nitrosylation: Mechanistic Links between Nitric Oxide Signaling and Atherosclerosis	10
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia	10
Cardiovascular Disease Burden among African Migrants	10
Obicetrapib—the Rebirth of CETP Inhibitors?	10
HDL as a Treatment Target: Should We Abandon This Idea?	10
Can Digital Health Solutions Fill in the Gap for Effective Guideline Implementation in Cardiovascular Disease Prevention: Hope or Hype?	10
The Atherosclerotic Plaque Microenvironment as a Therapeutic Target	9
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy	9
CETP Inhibitors: Should We Continue to Pursue This Pathway?	9
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?	9
Advances, Challenges, and Progress in Cardiac Rehabilitation in Chronic CVD Management	9
How to Handle Elevated Triglycerides: Life after PROMINENT	9
Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan	9
Statin Use and Hyperglycemia: Do Statins Cause Diabetes?	9
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment	9
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?	8
Family Meals and Cardiometabolic Risk Factors in Young Children	8
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence	8
Artificial Intelligence-Enabled Point-of-Care Echocardiography: Bringing Precision Imaging to the Bedside	8
JAM-A: Adhesion Receptor and Signaling Regulator in Atherosclerosis	8
LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?	8
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?	8
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?	8
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes	8
An Update on Nutrition Guidance for Cardiovascular Health	8
Gene Editing for the Treatment of Hypercholesterolemia	8
Myocardial Bridge and Atherosclerosis, an Intimal Relationship	7
Update on Sitosterolemia and Atherosclerosis	7
Correction to: Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	7
Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care	7
“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”	7
Correction to: Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	7
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy	7
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis	7
Health Literacy is Essential to ASCVD Prevention in Youth	7
Sport as Medicine for Dyslipidemia (and Other Risk Factors)	7
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes	7

Mechanisms Behind NAFLD: a System Genetics Perspective	7
Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?	7
Correction to: Built Environment and Cardiovascular Diseases – Insights from a Global Review	7
Biomarkers Differentiating Plaque Erosion from Stable Plaque	7
The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder	7
Eggs and Cardiovascular Disease Risk: An Update of Recent Evidence	7
Inclisiran: How Widely and When Should We Use It?	6
The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations	6
Statin Intolerance: an Overview of US and International Guidance	6
ADAMTS7: a Novel Therapeutic Target in Atherosclerosis	6
Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries	6
Tackling the Cardio-Kidney-Metabolic Burden in Cancer	6
Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context	6
Impact of Sex Differences on Lipids and Statin Utilization	6
Familial Combined Hyperlipidemia: Myth or Reality?	6
Incidental Finding of Coronary and Non-Coronary Artery Calcium: What Do Clinicians Need To Know?	6
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)	6
Mechanosensing and Mechanosignal Transduction in Atherosclerosis	6
Double-Trouble: Atherosclerotic Risk Factors and Congenital Heart Disease	6
Built Environment and Cardiovascular Diseases – Insights from a Global Review	6
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia	6
Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors	6
Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies	5
Telomere Length: Implications for Atherogenesis	5
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?	5
PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?	5
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future	5
Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes	5
The Role of Genetics in Advancing Cardiometabolic Drug Development	5
Updates in Drug Treatment of Severe Hypertriglyceridemia	5
AI in Adipose Imaging: Revolutionizing Visceral Adipose Tissue, Ectopic Fat, and Cardiovascular Risk Assessment	5
Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia	5
Updates in Small Interfering RNA for the Treatment of Dyslipidemias	5
Sex-based Differences in Complications Following Percutaneous Coronary Interventions	5
From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD’s Cardiometabolic Risks	5
Novel Therapeutics for Familial Chylomicronemia Syndrome	5
Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?	5
The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know	5
Lp(a): A Rapidly Evolving Therapeutic Landscape	5
Insight into the Mechanistic role of Colchicine in Atherosclerosis	5
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus	5